Protected percutaneous coronary intervention

CHA Hollywood Presbyterian Medical Center Ranked No. 2 in California for Coronary Interventional by Healthgrades

Retrieved on:

Wednesday, February 8, 2023

Emergency medical services, Physician, Hospital, Artery, U.S. National STEMI Receiving Centers, Protected percutaneous coronary intervention, Patient, STEMI, Healthgrades, Percutaneous, Emergency department, Percutaneous coronary intervention, Heart, CHA, LOS, Angioplasty, Nursing

LOS ANGELES, Feb. 8, 2023 /PRNewswire-PRWeb/ -- CHA Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, has been ranked as the second best hospital in California for coronary interventional procedures, according to a new analysis released by Healthgrades, the leading online resource that connects consumers, physicians, and health systems. Additionally, CHA HPMC has been recognized as one of America's 100 Best Hospitals for Coronary Intervention for two years in a row (2022-2023), America's 100 Best for Spine Surgery for three years in a row (2021-2023), and a recipient of Orthopedic Surgery Excellence Award (2023).

Key Points:

LOS ANGELES, Feb. 8, 2023 /PRNewswire-PRWeb/ -- CHA Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, has been ranked as the second best hospital in California for coronary interventional procedures, according to a new analysis released by Healthgrades, the leading online resource that connects consumers, physicians, and health systems.
Percutaneous coronary intervention is a minimally invasive, non-surgical procedure used to treat blockages in the coronary (heart) arteries and improve blood flow to the heart.
Hospitals ranked among the top in the state by Healthgrades are recognized for providing patients with superior clinical outcomes in coronary intervention procedures, including angioplasty with stent.
For the state ranking analysis, Healthgrades evaluated clinical performance for nearly 4,500 hospitals nationwide focusing on 18 key specialties across a mix of chronic, urgent, and surgical areas.

First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP

Retrieved on:

Wednesday, October 28, 2020

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump.

Key Points:

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump.
Impella ECP is the smallest heart pump in the world.
View the full release here: https://www.businesswire.com/news/home/20201028005398/en/
Impella ECP is the worlds smallest heart pump.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

Retrieved on:

Friday, October 16, 2020

Medical devices, Health, Clinical trials, Research, Science, Cardiology, Medical specialties, Medicine, Interventional cardiology, Medical devices, Medical technology, Cardiology, Abiomed, Prosthetics, Impella, Protected percutaneous coronary intervention

Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.

Key Points:

Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.
This study suggests that in right heart failure, reducing the time between shock onset and initiation of Impella RP is a key element of proper patient support.
A second study presented at TCT aims to help clinicians identify early triggers of right heart failure.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

Retrieved on:

Friday, October 16, 2020

Medical devices, Health, Surgery, Clinical trials, Cardiology, Biotechnology, Medicine, Interventional cardiology, Medical devices, Medical specialties, Medical technology, Cardiology, Impella, Prosthetics, Abiomed, Peripheral Component Interconnect, Protected percutaneous coronary intervention

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.

Key Points:

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.
Researchers found an 18% relative improvement in overall survival in the recent cohort, indicating an associated benefit to placing Impella pre-PCI.
It found that placing Impella pre-PCI in AMICS patients is associated with higher survival than placing Impella post-PCI, especially in women.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes

Retrieved on:

Thursday, October 15, 2020

Health, Medical devices, Hospitals, Surgery, General Health, Cardiology, Biotechnology, Medicine, Interventional cardiology, Medical devices, Medical specialties, Medical technology, Cardiology, Prosthetics, Impella, Abiomed, Protected percutaneous coronary intervention

PROTECT III is an ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI.

Key Points:

PROTECT III is an ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI.
PII-like patients in PROTECT III had improved 90-day MACCE rates, compared to PROTECT II patients (15% vs. 21.9%, p=0.035).
PROTECT IV will compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

Retrieved on:

Wednesday, October 14, 2020

Medical devices, Health, Other Health, Clinical trials, Cardiology, Biotechnology, Interventional cardiology, Medical devices, Circulatory system, Medical specialties, Cardiovascular system, RTT, Cardiology, Aging-associated diseases, Protected percutaneous coronary intervention, Impella, Ejection fraction, Heart failure

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella -supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up.

Key Points:

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella -supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up.
(see figure 1)
Restore EF demonstrates Impella-supported PCI patients have shown a significant LVEF improvement at 90 days.
Restore EF is part of a growing body of evidence demonstrating Protected PCI with Impella is associated with improvements in LVEF and heart failure symptoms.
Findings from Restore EF will be used to inform the study protocol for the upcoming PROTECT IV Randomized Controlled Trial .

TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients

Retrieved on:

Thursday, October 8, 2020

Health, Clinical trials, Cardiology, Medical devices, Medical specialties, Medicine, Clinical medicine, Interventional cardiology, Medical devices, RTT, Cardiology, Prosthetics, Impella, Abiomed, Protected percutaneous coronary intervention

The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with SmartAssist are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Key Points:

The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with SmartAssist are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
The Impella RP has not been cleared or approved for the treatment of acute right heart failure or decompensation caused by complications related to COVID-19.
Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Retrieved on:

Friday, June 5, 2020

View the full release here: https://www.businesswire.com/news/home/20200605005049/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20200605005049/en/
FDA Approves Abiomeds First-in-Human Trial of Impella ECP, Worlds Smallest Heart Pump
Impella ECP is the worlds smallest heart pump.
The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with Smart Assist are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
The Impella RP is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

Retrieved on:

Monday, June 1, 2020

Health, FDA, Medical devices, Infectious diseases, Surgery, Cardiology, Biotechnology, Medicine, Medical specialties, Interventional cardiology, Medical devices, Medical technology, Cardiology, Prosthetics, Impella, Abiomed, Protected percutaneous coronary intervention

(Photo: Business Wire)

Key Points:

(Photo: Business Wire)
Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure.
Since the onset of the COVID-19 pandemic, Impella RP has become a therapeutic choice for clinicians treating certain COVID-19 patients suffering right heart failure.
The Impella RP is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

Retrieved on:

Tuesday, May 19, 2020

Medical devices, Health, Hospitals, Surgery, General Health, Cardiology, Medicine, Interventional cardiology, Medical devices, Medical technology, Medical specialties, Cardiology, Prosthetics, Impella, Abiomed, Protected percutaneous coronary intervention

View the full release here: https://www.businesswire.com/news/home/20200519005627/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20200519005627/en/
The data presented is from an adjunct study of PROTECT III , the ongoing, prospective FDA post-approval study for Impella in high-risk PCI.
The study analyzed 1,028 patients supported with Impella 2.5 or Impella CP (971 in Protected PCI group and 57 in bailout group).
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.
Impella BTR, Impella 5.5, Impella ECP, CVAD Study, DTU STEMI Study and SmartAssist are pending trademarks of Abiomed, Inc.